Related Experiment Video
Updated: Jul 15, 2026
08:23
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Genetic polymorphisms associated with priapism in sickle cell disease
Laine Elliott1, Allison E Ashley-Koch, Laura De Castro
1Department of Medicine, Duke University and VA Medical Centers, Durham, NC 27710, USA.
British Journal of Haematology
|April 6, 2007
Summary
Genetic factors influence priapism risk in sickle cell disease (SCD) patients. Key genes in TGF-beta, coagulation, and cell adhesion pathways are associated with increased priapism incidence.
Area of Science:
- Genetics
- Hematology
- Urology
Background:
- Priapism affects 30-45% of males with sickle cell disease (SCD).
- Genetic risk factors contributing to priapism in SCD are not well understood.
Purpose of the Study:
- To investigate genetic polymorphisms associated with priapism incidence in adult male SCD patients.
- To identify specific genes and pathways involved in priapism development in SCD.
Main Methods:
- Genomic analysis of 199 adult male patients with Hb SS and Hb Sbeta(0)-thalassaemia.
- Examined candidate genes involved in adhesion, coagulation, inflammation, cell signaling, nitric oxide biology, and the klotho gene.
- Utilized single nucleotide polymorphism (SNP) analysis and statistical association testing.
Main Results:
- Significant associations found for SNPs in TGFBR3, AQP1, ITGAV, and F13A1.
- Associations with TGFBR3, AQP1, and ITGAV remained significant after multiple testing correction.
- Identified potential roles for the TGFbeta pathway, coagulation, cell adhesion, and cell hydration.
Conclusions:
- Genetic variations in TGFBR3, AQP1, and ITGAV are linked to priapism risk in SCD.
- These findings highlight the importance of specific biological pathways in priapism pathogenesis.
- Further research into these genetic factors could inform preventative strategies for priapism in SCD.
Related Concept Videos
01:49Multiple Allele Traits
The Concept of Multiple Allelism
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...